

## 7. Literatur

- 1 Worth H, Leitlinien der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem. Pneumologie, 2002; 56: 703-737.
- 2 Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med, 2001; 163:1256-1276. (update 2004: <http://www.goldcopd.com>)
- 3 Celli BR, MacNee W et al. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Resp J, 2004 ; 23: 932-946.
- 4 European Respiratory Society. European Lung White Book. Lausanne, Switzerland: European respiratory Society, 2003: 1-182.
- 5 Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat. Med., 1998; 4: 1241-1243.
- 6 Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Stat., 1998; 101-428.
- 7 Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med, 2000; 343: 269-280.
- 8 Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest, 2000; 117:5S-9S.
- 9 O'Connor GT, Sparrow D, Weiss ST. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary-function decline: the Normative Aging Study. Am J Respir Crit Care Med, 1995; 152:87-92.

- 10 Tashkin DP, Detels R, Simmons M. The UCLA population studies of chronic obstructive respiratory disease: XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. *Am J Respir Crit Care Med*, 1994; 149:1209-1217.
- 11 Burrows B, Knudson P, Cline MD et al. Quantitative relationship between cigarette smoking and ventilatory function. *Am Rev Respir Dis*, 1977; 115: 195-205.
- 12 Fletscher C, Peto R. The natural history of chronic airflow obstruction. *Br Med J*, 1977; 1: 1645-8.
- 13 Doll R, Peto R, Wheatley K et al. Mortality in relation to smoking: 40 years' observations on male British doctors. *BMJ*, 1994; 309:901-911.
- 14 Doll R. Risk from tobacco and potentials for health gain. *Int. J. Tuberc. Lung Dis*, 1999; 3:90-99.
- 15 Coultas DB. Passive smoking and risk of adult asthma and COPD : an update. *Thorax*, 1998; 53: 381-387.
- 16 Rothenbacher D, Arndt V, Fraisse E et al., U. Daniel. Chronic respiratory disease morbidity in construction workers: patters and prognostic significance for permanent disability and overall mortality. *Eur Respr J*, 1997 ; 10:1093-1099.
- 17 Becklake MR. Occupational exposure: evidence for a causal association with chronic obstructive pulmonary disease. *Am Rev Respir Dis*, 1989; 140 : S85-S91.
- 18 Chen JC, Mannino MD. Worldwide epidemiology of chronic obstructive pulmonary disease. *Current Opin Pulmon Med*, 1999; Pforte, A. COPD- Chronisch- obstruktive Lungenerkrankungen und Komplikationen.
- 19 American Thoracic Society. What constitutes an adverse health effect of air pollution? Official statement of the American Thoracic Society. *Am J Respir Crit. Care Med.*, 2000; 161: 665-673.

- 20 Dockery DW, Pope CA. Acute respiratory effects of particulate air pollution. *Annu Rev Public Health*, 1994; 15: 107-132.
- 21 Touloumi G, Katsouyanni K, Zmirou D et al. Short term effects of ambient oxidant exposure on mortality: a combined analysis within the APHEA project. *Air pollution and Health: a European Approach. Am J Epidemiol.*, 1997; 146 : 177-185.
- 22 Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. *Eur Respr J*, 1999 ; 13: 1109-1114.
- 23 Rogot E, Sorlie PD, Johnson NJ. Life expectancy by employment status, income an education in the National longitudinal Mortality Study. *Public Health Rep.*, 1992; 107. 457-461.
- 24 Viegi G, Paoletti R, Prediletto R et al. Prevalence of respiratory symptoms an an unpolluted area of northern Italy. *Eur Respir J*, 1998 ; 1: 311-318.
- 25 Wang Q, Bourbeau J. Outcomes and health related quality of life following hospitalization for an acute exacerbation of COPD. *Respirology*, 2005; 10 (3): 334- 340.
- 26 Gan WQ, Man SPF, Senthilselvan A et al. Association between chronic obstructive pulmonary disease und systemic inflammation: a systemic review and a metaanalysis. *Thorax* 2004; 59: 574-580.
- 27 Debigare R, Marquis K, Coté CH et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. *Chest*, 2003; 124: 1365-1372.
- 28 Strachan DP, Cox D, Erzinclioglu SW et al. Ventilatory function and winter fresh fruit consumption in a random sample of British adults. *Thorax*, 1991; 46: 624-629.

- 29 Shahar E, Folsom AR, Melnick SL et al. Dietary n-3 polyunsaturated fatty acids and smoking- related chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators. *N Engl J Med*, 1994; 331: 228-233.
- 30 Gold DR, Wang X, Wypij D et al. Effects of cigarette smoking on lung function an adolescent boys and girls. *N Engl J Med*, 1996; 335: 931-937.
- 31 Prescott E, Bjerg AM, Anderson PK et al. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. *Eur Respir J*, 1997 ; 10: 822-827.
- 32 Alpha-1-antitrypsin deficiency: emorandum from a WHO meeting. *Bull World Health Organ*, 1997; 75: 397-415.
- 33 Silverman EK, Chapman HA, Drazen JM et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. *Am J Respir Crit Care Med*, 1998; 157: 1770-1778.
- 34 Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. *Am J Respir Crit Care Med*,1997; 156:1436-1439.
- 35 Morgan WJ. Maternal smoking and infant lung function. Further evidence for an in utero effect. *Am J Respir Crit Care Med*, 1998; 158: 689-690.
- 36 Svanes C, Omenaas E, Heuch JM et al. Birth characteristics and asthma symptoms in young adults: results from a population based cohort study in Norway. *Eur Respir J*, 1998 ; 12: 1366-1370.
- 37 Xu X, Rijcken B, Shouten JP et al. Airway responsivness and development and remission of chronic respiratory symptoms in adults. *Lancet*, 1997; 350: 1431-1434.
- 38 Boezen HM, Jansen DF, Postma DS. Sex and gender differences an lung development and their clinical significance. *Chest*, 2004; 25 (2): 237- 245.

- 39 Doherty DE. The pathophysiologie of airway dysfunction. *Am J Med*, 2004; 117: 11S-23S.
- 40 Finkelstein R, Fraser RS, Ghezzo H et al. Alveolar inflammation and its relation to emphysema in smokers. *Am J Respir Crit Care Med*, 1995; 152: 1666-1672.
- 41 Saetta M, Di Stefano A et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 1998; 157: 822- 826.
- 42 Hogg J, Coxon HO, Pare PD. The nature of small- airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med*, 2004; 26: 2645-2653.
- 43 Barnes PJ. Mediators of Chronic Obstructive Pulmonary Disease. *Pharmacol Rev*, 2004; 56: 515- 548.
- 44 Barnes PJ. Mechanism in COPD: differences from Asthma. *Chest*, 2000; 117: 10S- 14S.
- 45 Jeffery PK. Structural and inflammatory changes in COPD : a comparison with asthma. *Thorax*, 1998; 53: 129- 136.
- 46 Barnes PJ. Small airways in COPD. *N Engl J Med*, 2004; 26: 2635-2637.
- 47 John M, Hörnig S, Witt C et al. Anemia and inflammation in chronic obstructive pulmonary disease. *Chest*, 2005; 127: 825- 829.
- 48 John M, Lange A, Hörnig S et al. Prevalence of anemia in Chronic Obstructive Pulmonary Disease: Comparison to other chronic diseases. *Int J Cardiol*, 2006; im Druck.
- 49 Augusti AGN. COPD, a multicomponent disease: implications for management. *Respir Med.* , 2005; 99 (6): 670-682.

- 50 Schols AW, Soeters PJ, Dingemans AMC et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. *Am Rev Respir Dis*, 1993; 147: 1151- 1156.
- 51 Schols AW, Slangen J, Volovics L et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 1998; 157: 1791- 1797.
- 52 Schols AM. Nutrition in chronic obstructive pulmonary disease. *Curr Opin Pulm Med*, 2000; 6: 110- 115.
- 53 Celli BR, Cote CG, Marin JM et al. The body mass index, airflow obstruction, dyspnoea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med*, 2004; 350: 1105- 1012.
- 54 Nelson S, Summer WR. Innate immunity, cytokines and pulmonary host defense. *Infect Dis Clin North Am*, 1998; 12: 555- 567.
- 55 Gordon S. The role of the macrophage in immun regulation. *Res Immuno*, 1998; 149: 685- 688.
- 56 Lohmann- Matthes ML, Steinmüller C, Franke- Ullmann G. Pulmonary Macrophages. *Eur Respir J*, 1994; 7: 1678- 1689.
- 57 Kelley J. State of the art – cytokines of the lung. *Am Rev Respir Dis*, 1990; 141: 755- 788.
- 58 Arai K, Lee F, Miyajima A et al. Cytokines : coordinators of immune and inflammatory response. *Annu Rev Biochem*, 1990; 12: 735- 773.
- 59 Dinarello CA. Interleukin –1 and interleukin-1 antagonism. *Blood*, 1991; 77: 1627-1652.
- 60 Saklatvala J. Intracellular signalling mechanism of interleukin-1 and tumor necrosis factor: possible targets for therapy. *Brit Med Bull*, 1995; 51: 402- 418.

- 61 Lipsky PE, Thompson PA, Rosenwasser LJ et al. The role of IL-1 in human B-cell activation: inhibition of B-cell proliferation and the generation of immunoglobulin-secreting cells by antibody against human leukocytic pyrogen. *J Immunol*, 1983; 130: 2708- 2714.
- 62 Dinarello CA, Wolff SM. The role of interleukin-1 in disease. *N Engl J Med*, 1993; 328: 106- 113.
- 63 Russell RE, Thorley A, Culpitt SV et al. Alveolar macrophages- mediated elastolysis: the role of matrix metalloproteinases, cysteine and serine proteases. *Am J Physiol Lung Cell Mol Physiol*, 2000; 283: L867-873.
- 64 Rusznak C, Mills PR, Devalia JL et al. Effect of cigarette smoke on the permeability and IL-1 $\beta$  and sICAM-1 release from cultured human bronchial epithelial cells of never- smokers, smokers and patients with chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol*, 2000; 23: 530-536.
- 65 Lucey EC, Keane J, Kuang PP et al. Severity of elastase- induced emphysema is decreased in tumor necrosis factor- $\alpha$  and interleukin- 1 $\beta$  receptor- deficient mice. *Lab Investig*, 2002; 82: 79-85.
- 66 Gough NM, Nicola NA. Granulocyte-macrophage colony-stimulating factor. *Immunology series*, 1990; 49: 111-153.
- 67 Balbi B, Bason C, Balleari E et al. Increased bronchoalveolar granulocytes and granulocyte/ macrophage colony- stimulating factor during exacerbations of chronic bronchitis. *Eur Respir J*, 1997; 10: 846- 850.
- 68 Culpitt SV, Rogers DF, Shah P et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2003; 167: 24-31.
- 69 Farrar MA, Schreiber RD. The molecular cell biology of interferon - $\gamma$  and its receptor. *Annu Rev Immunol*, 1993; 11: 571-611.

- 70 Robinson BW, McLemore TL, Crystal RG et al. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patient with pulmonary sarcoidosis. *J Clin Invest*, 1985; 75: 1488-1495.
- 71 Johnson HM, Farrar WL. The role of a gamma interferon-like lymphokine in the activation of T-cells for expression of interleukin-2 receptors. *Cell Immunol*, 1983 ; 75: 154-159.
- 72 Chomarat P, Risoan MC, Banchereau J et al. Interferon- $\gamma$  inhibits interleukin 10 production by monocytes. *J Exp Med*, 1993; 177 : 523-527.
- 73 Hart PH, Whitty GA, Piccoli DS et al. Control by IFN $\gamma$  and PGE<sub>2</sub> of TNF $\alpha$  and IL-1 production by human monocytes. *Immunology*, 1989; 66: 376-527.
- 74 Murray, HW, Rubin BY, Rothermel CD. Killing of intracellular leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon- $\gamma$  is the activating lymphokine. *J Clin Invest*, 1983; 72: 1506-1510.
- 75 Lei D, Lancaster JR, Joshi MS et al. Activation of alveolar macrophages and lung host defenses using transfer of the interferon-gamma gene. *Am J Physiol*, 1997; 272: L852-L859.
- 76 Tzanakis N, Chrysofakis G, Tsoumakidou M et al. Induced sputum CD8+ T-lymphocyte subpopulations in chronic obstructive pulmonary disease. *Respir Med*, 2004; 98: 57-65.
- 77 Panzner P, Lafitte JJ, Tsiopoulos A et al. Marked up-regulation of T lymphocytes and expression of interleukin-9 in bronchial biopsies from patients with chronic bronchitis with obstruction. *Chest*, 2003; 124: 1909-1915.
- 78 Di Stefano A, Caramori G, Capelli A et al. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. *Eur Respir J*, 2004; 24: 78-85.



- 79 Wang Z, Zheng T, Zhu Z et al. Interferon- $\gamma$  induction of pulmonary emphysema in the adult murine lung. *J Exp Med*, 2000; 192: 1587-1600.
- 80 Majori M, Corradi M, Caminati A et al. Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. *J Allergy Clin Immunol*, 1999; 103: 458-462.
- 81 Cook DN. The role of MIP-1 $\alpha$  in inflammation and hematopoiesis. *J Leukoc Biol*, 1996; 59: 61-66.
- 82 Wolpe SD, Cerami A. Macrophage inflammatory protein 1 and 2: members of a novel superfamily of cytokines. *FASEB*, 1989; 3: 2565-2572.
- 83 Capelli A, Di Stefano A, Gnemmi I et al. Increased MCP-1 and MIP- 1 $\beta$  in bronchoalveolar lavage fluid of chronic bronchitis. *Eur respir J*, 1999; 14: 160-165.
- 84 Fiorentino DF, Zlotnik A, Mosman TR et al. IL-10 inhibits cytokine production by activated macrophages. *J Immunol*, 1991; 147: 3815-2822.
- 85 Cassatella MA, Meda L, Gasperini S et al. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. *J Exp Med*, 1994; 179: 1695-1699.
- 86 John M, Oltmanns U, Liebers U et al. MIP-1 $\alpha$  release from alveolar macrophages is inhibited by endogenous IL-10 in pneumonia and interstitial lung diseases. *Am J Respir Crit Care Med*, 1999; 159: A928.
- 87 De Waal Malefyt R, Abrams J, Bennett B et al. Interleukin-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. *J Exp Med*, 1991; 174: 1209-1220.
- 88 Wang P, Wu P, Siegel MI et al. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. *J Immunol*, 1994; 153: 811-816.

- 89 Berkman N, M. John M, Roesems G. Inhibition of macrophage inflammatory protein-1 $\alpha$  expression by IL-10. *J Immunol*, 1995; 155: 4412-4418.
- 90 Takanashi S, Hasegawa Y, Kanehira Y et al. Interleukin- 10 level in sputum is reduced in bronchial asthma, COPD and smokers. *Eur Respir J*, 1999; 14: 309-314.
- 91 Lim S, Roche N, Oliver BG et al. Balance of matrix metalloproteinase-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by IL-10. *J Respir Crit Care Med*, 2000; 162: 1355-1360.
- 92 Lacraz S, Nicod LP, Chicheportiche R et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. *J Clin Investig*, 1995; 96: 2304-2310.
- 93 Mostafa ME, Chollet- Martin S, Oudghriri M et al. Effects of interleukin- 10 on monocytes/ endothelial cells adhesion and MMP-9/TIMP-1 secretion. *Cardiovasc Res*, 2001; 49: 882-890.
- 94 Williams L, Bradley L, Smith A et al. Signal transducer and activator of transcription 3 is the dominant mediator of the anti- inflammatory effects of IL-10 in human macrophages. *J Immunol*, 2004; 172: 567-576.
- 95 Blusse van Oud Albas A, Van der Linden-Schrever B, van Furth R. Origin and kinetics of pulmonary macrophages during inflammatory reaction induced by intra-alveolar administration of aerosolized heat-killed BCG. *Am Rev Respir Dis*, 1983; 128: 276-281.
- 96 Shapiro SD. The macrophage in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 1999; 160: S29-S32.
- 97 Barnes PJ. Macrophages as orchestrators of COPD. *J COPD*, 2004; 1: 59-70.

- 98 Punturieri A, Filippov S, Allen E et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. *J Exp Med*, 2000; 192: 789-800.
- 99 Di Stefano A; Caramori G, Capelli A et al. Increased expression of NF- $\kappa$ B in bronchial biopsies from smokers and patients with COPD. *Eur Respir J*, 2002; 20: 556-563.
- 100 Fadok VA, Bratton DL, Rose DM et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. *Nature*, 2000; 405: 85-90.
- 101 Retamales I, Elliott WM, Meshi B et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. *Am J Respir Crit Care Med*, 2001; 164: 469-473.
- 102 Meshi B, Vitalis TZ, Ionescu D et al. Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection in the lung inflammatory response. *Am J Respir Cell Mol Biol*, 2002; 26: 52-57.
- 103 Tomita K, Barnes PJ, Adcock IM. The effect of oxidative stress on histone acetylation and IL-8 release. *Biochem Biophys Res Commun*; 2003; 301: 572-577.
- 104 Di Stefano A, Capelli A, Lusuardi M et al. Severity of airflow limitation is associated with severity of airflow inflammation in smokers. *Am J Respir Crit Care Med*, 1998; 158: 1277-1285.
- 105 Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1 $\beta$  induced histone H<sub>4</sub> acetylation on lysines 8 and 12. *Mol Cell Biol*, 2000; 20: 6891-6903.
- 106 Ito K, Lim S, Caramori G et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. *FASEB J*, 2001; 25: 1100-1102.

- 107 Majo J, Ghezzi H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. *Eur Respir J*, 2001; 17: 946-953.
- 108 Saetta M, Mariani M, Panina-Bordignon P et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2002; 165: 1404-1409.
- 109 Kim WD, Kim WS, Koh Y et al. Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. *Chest*, 2002; 122: 437-444.
- 110 Cosio MG, Majo J. Inflammation of the airways and lung parenchyma in COPD: role of T cells. *Chest*, 2002; 121: 160S-165S.
- 111 Hashimoto S, Kobayashi A, Kooguchi K et al. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. *Am J Respir Crit Care Med*, 2000; 161: 237-243.
- 112 Takubo Y, Guerassimov A, Ghezzi H et al.  $\alpha$ 1-Antitrypsin determines the pattern of emphysema and function in tobacco smoke. Exposed mice: parallels with human disease. *Am J Respir Crit Care Med*, 2002; 166: 1596-1603.
- 113 Calverley P, Pauwels R, Vestbo et al. Combined salmeterol and fluticasone in treatment of chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet*, 2003; 361: 449-456.
- 114 National Emphysema Treatment Trial Research Group. A randomised trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med*, 2003; 348: 2059-2073.
- 115 Brunton S, Carmichael BP, Colgan R et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. *Am J Manag Care*, 2004; 10: 689-696.

- 116 The TORCH Study Group. The TORCH survival study protocol. *Eur Respir J*, 2004 ; 24: 206-210.
- 117 Sin DD, Lacy P, York E et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2004; 170: 760-765.
- 118 Creutzberg EC, Wouters EF, Mostert R et al. A role for anabolic steroids in the rehabilitation of patient with COPD ? *Chest*, 2003; 124: 1733-1742.
- 119 Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. *Lancet*, 2004; 364: 985-996.
- 120 Baser Y, de Shazo RD, Barkman HW et al. Lidocaine effects on Immunocompetent cells. Implications for studies of cells obtained by bronchoalveolar lavage. *Chest*, 1982; 82: 323-328.
- 121 Jones PW, Quirk FH, Baveystock CM et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. *Am Rev Respir DIS*, 1992; 145: 1321-1327.
- 122 Jones PW. Health status measurement in chronic obstructive pulmonary disease. *Thorax*, 2001; 56: 880-887.
- 123 Leach CL. Improved delivery of inhaled steroids to the large and small airways. *Resp Med*, 1998; 92 (Supplement A): 3-8.
- 124 Rote Liste. Arzneimittelverzeichnis der Pharmazeutischen Industrie, des Verbandes forschender Arzneimittelhersteller, des Bundesfachverbandes der Arzneimittelhersteller und des Verbandes aktiver Pharmaunternehmen. Editio Cantor Verlag Aulendorf, 2006.
- 125 Barnes PJ. New therapies for chronic obstructive pulmonary disease. *Thorax*, 1998; 53: 137-147.
- 126 Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2000; 161: 342-344.

- 127 Johnson M. The beta adrenorezeptoren. *Am J Respir Crit Care Med*, 1998; 158: 146- 153.
- 128 Man PSF, Sin DD. Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. Is there a clinical benefit? *Drugs*, 2005; 65 (5): 579-591.
- 129 Reichert HM, Tuckermann JP, Gottlicher M et al. Repression of inflammatory response in the absence of DNA binding by the glucocorticoid receptor. *EBMO J*, 2001; 20: 7168- 7173.
- 130 Vestbo J, Sorensen T, Lange P et al. Long term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet*, 1999; 353: 1819-1823.
- 131 Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. *N Engl J Med*, 2000; 343: 1902- 1909.
- 132 Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ*, 2000; 320: 1297- 1303.
- 133 Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2001; 164: 580- 584.
- 134 Van der Valk P, Monninkhof E, van der Palen J et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. *Am J Respir Crit Care Med*, 2002; 166: 1358- 1563.
- 135 Hattotuwa KL, Gizycki MJ, Ansari TW et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double- blind, placebo controlled biopsy study. *Am J Respir Crit Care Med*, 2002; 165: 1592- 1596.

- 136 Hospers JJ, Postma DS, Rijcken B et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. *Lancet*, 2000; 356: 1313- 1317.
- 137 Johnell O, Pauwls R, Lofdahl CG et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbohaler. *Eur Respir J*, 2002; 19: 1058-1063.
- 138 Kamin WE, Genz T, Roeder S et al. Mass output and particle size distribution of glucocorticosteroids from different inhalation devices depending on vario inspiratory parameters. *J Aerosol Med*, 2002; 15 (1): 65-73.
- 139 Seeger W, Schulz R. Inhalation combination therapy in chronic obstructive lung disease. TRISTAN study. *Internist (Berl.)*, 2004; 45 (6): 727-728.
- 140 Jones PW. Clinical Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. *Proc Am Thorac Soc*, 2004; 1: 167-170.
- 141 Esteban C, Moraza J, Quiñtana JM et al. Use of medication and quality of life among patients with COPD. *Resp Med*, 2006; 100 (3): 487- 495.